Payment overview · 2025
General Payments
$365.25
8 reported records · 6 companies
Healthcare provider profile · identity verified
Heather Richardson, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FRIES, VA · NPI 1346553575
Verified facts
What the public records show
CMS Open Payments records show Heather Richardson, FNP-BC received $365.25 in general payments during 2025 across 8 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tudorza Pressair by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 34.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.16 | 25.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.53 | 17.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.85 | 12.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.55 | 5.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.16 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.25 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.16 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $65.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 660 | 83 |
| Omeprazole | Omeprazole | 486 | 95 |
| Gabapentin | Gabapentin | 481 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 80 |
| Furosemide | Furosemide | 347 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 341 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 326 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 71 |
| Clonazepam | Clonazepam | 309 | 35 |
| Famotidine | Famotidine | 290 | 49 |
| Metformin Hcl | Metformin Hcl | 285 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 53 |
| Losartan Potassium | Losartan Potassium | 223 | 54 |
| Prednisone | Prednisone | 216 | 97 |
| Azithromycin | Azithromycin | 206 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 43 |
| Trazodone Hcl | Trazodone Hcl | 205 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 30 |
| Sertraline Hcl | Sertraline Hcl | 185 | 35 |
| Lorazepam | Lorazepam | 183 | 28 |
| Montelukast Sodium | Montelukast Sodium | 176 | 33 |
| Lisinopril | Lisinopril | 174 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 25 |
| Amoxicillin | Amoxicillin | 141 | 86 |
| Tramadol Hcl | Tramadol Hcl | 134 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 20 |
| Simvastatin | Simvastatin | 127 | 28 |
| Potassium Chloride | Potassium Chloride | 126 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 24 |
| Meloxicam | Meloxicam | 122 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 26 |
| Cephalexin | Cephalexin | 115 | 75 |
| Buspirone Hcl | Buspirone Hcl | 112 | 17 |
| Atenolol | Atenolol | 110 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 17 |
| Farxiga | Dapagliflozin Propanediol | 105 | 17 |
| Allopurinol | Allopurinol | 104 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 28 |
| Ozempic | Semaglutide | 96 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 16 |
| Ondansetron Odt | Ondansetron | 93 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 21 |
| Glipizide | Glipizide | 86 | 25 |
| Topiramate | Topiramate | 85 | 19 |
| Baclofen | Baclofen | 84 | 36 |
| Risperidone | Risperidone | 83 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 17 |
| Glimepiride | Glimepiride | 82 | 16 |
| Eliquis | Apixaban | 81 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 26 |
| Pregabalin | Pregabalin | 80 | 12 |
| Carvedilol | Carvedilol | 77 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 15 |
| Spironolactone | Spironolactone | 74 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 16 |
| Vraylar | Cariprazine Hcl | 68 | suppressed |
| Lovastatin | Lovastatin | 67 | 16 |
| Lamotrigine | Lamotrigine | 65 | 14 |
| Divalproex Sodium | Divalproex Sodium | 64 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 41 |
| Ibuprofen | Ibuprofen | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 17 |
| Estradiol | Estradiol | 50 | 16 |
| Fluconazole | Fluconazole | 50 | 26 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | 14 |
| Temazepam | Temazepam | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Nystatin | Nystatin | 39 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 31 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 31 |
| Misoprostol | Misoprostol | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 17 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.25 · 8 records | Otsuka America Pharmaceutical, Inc. | Auvelity, BREZTRI, CAPLYTA, FANAPT, MOUNJARO, REXULTI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error